IMMUNOTHERAPY HUB · BTCE RESOURCES
Bispecific T-Cell Engagers, Decoded for Every Care Setting
Curated, practice-ready resources supporting the safe, effective implementation of bispecific T-cell engager therapies (BTCE) therapies — from foundational overviews to agent-specific insights and downloadable SOPs.
3
Core Sections
10
Agent Profiles
20+
Example SOPs
5
CE Webinars
Agent-Specific Resources
Example SOPs & Documents
CE Webinars
Recommended Reading
Additional Learning
Overview of BTCEs
OUR PURPOSE
Empowering Teams to Implement Bispecific T-Cell Engager Therapies
Explore practical resources designed to support the safe and effective implementation of bispecific T-cell engager (BTCE or BiTE) therapies across care settings. Build foundational knowledge, explore agent-specific guidance, and learn from real-world SOPs developed by oncology practices.
Simplified mechanism:
A bispecific T-cell engager bridges a T cell and a tumor cell to help drive a targeted immune response.
T-Cell
Tumor Cell
BTCE
WHERE TO START
Explore by Resource Type
Our resources are divided into three main sections — start wherever fits your team’s current needs.
Overview of BTCEs
Essential knowledge on BTCEs — key insights and practical guidance for effective clinical implementation.
Agent-Specific Resources
Our “Up Close” series dives deeper into individual agents — dosing, REMS, and administration details.
Example SOPs and Documents
De-identified, real-world protocols and procedures shared by NCODA member practices of every size.
02
03
01
01 · FOUNDATIONS
Overview of BTCEs
Essential knowledge on BTCEs — key insights and practical guidance for effective clinical implementation.
Comparison of Bispecific T-Cell Engagers (BTCEs)
A quick-take guide to the essential details of bispecific T-cell engagers.
Engaging with Bispecific T-Cell Engagers
How these agents function, their dosing schedules, notable side effects, and REMS requirements for certain agents.
Putting Bispecific T-Cell Engagers into Action
A practical guide for operationalizing BTCEs in your practice.
Clearing Up Confusion Around Bispecific T-Cell Engagers
Clarifying terminology and highlighting the differences between observation periods and supportive care.
02 · UP CLOSE SERIES
Agent-Specific Resources
Dive deeper with focused, agent-level insight — dosing, REMS considerations, and administration details for each BTCE.
Blinatumomab
BLINCYTO®
Elranatamab-bcmm
ELREXFIO™
Epcoritamab-bysp
EPKINLY®
Glofitamab-gxbm
COLUMVI™
Linvoseltamab-gcpt
LYNOZYFIC™
Mosunetuzumab-axgb
LUNSUMIO™
Talquetamab-tgvs
TALVEY®
Tarlatamab-dlle
IMDELLTRA™
Tebentafusp-tebn
KIMMTRAK®
Teclistamab-cqyv
TECVAYLI®
03 · REAL-WORLD PRACTICE
Example SOPs and Documents
Sample protocols and procedures shared by NCODA member practices - de-identified, with details on clinic size to help you find the right fit.
Education
• Staff Education for Using Bispecific T-Cell Engagers
Mid-sized, Community
• Patient Education (Coming Soon)
Mid-sized, Partial Integrated, Community
Inpatient Use of BTCE
• Inpatient Use of Bispecific T-Cell Engagers
Large Academic Center
AE Management
• Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management
Mid-sized, Rural Community
• Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management
Large Community
• Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management
Large Academic Center
Coming Soon →
On-Call & Triaging Practices
• On-Call Symptom Interventions for Patients Receiving Bispecific T-Cell Engagers
Mid-sized, Community
• Telephone Triage of Patients Undergoing Bispecific T-Cell Engager Therapy
Mid-sized, Community
• On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers
Mid-sized, Community
Ordering & Billing
• Bispecific T-Cell Engager Ordering and REMS Compliance
Mid-sized, Community Satellites
• Bispecific T-Cell Engager Billing Procedure
Mid-sized, Community
Transitioning Patients
• Transitioning Patients Between Care Settings
Mid-sized, Partial Integrated, Community
Coming Soon →
• Bispecific T-Cell Engager Neurotoxicity Management
Mid-sized, Rural Community
• Bispecific T-Cell Engager Neurotoxicity Management
Large Community
• Bispecific T-Cell Engager Neurotoxicity Management
Large Academic Center
ON-DEMAND LEARNING
CE Webinars
Earn continuing education credit while learning directly from practicing clinicians and pharmacists.
Explore the Full CE Library
Advanced Practice Provider and Pharmacy Perspectives on BTCEs
Nicholas Bouchard, PharmD · Denise Lougee, MS-PAS, RPA-C
1 CE CREDIT
Adverse Effects Associated with Bispecific T-Cell Engagers
Nicholas Bitz, PharmD, MBA · C. Brooke Adams, PharmD, BCOP
1 CE CREDIT
Education and Training for Staff and Patients Regarding BTCEs
Eden Biltibo, MD, MS · Kristen Kingma, DNP, RN, OCN
1 CE CREDIT
Patient’s EHR and BTCE Therapy: Documentation and Billing
Stephanie S. Waddoups, RN, BSN
1 CE CREDIT
Outpatient Step-Up Dosing of Bispecific T-Cell Engagers
Tara Graff, DO, MS · Kelly Brunk, PharmD, BCOP
ON DEMAND
ADDITIONAL LEARNING
Related Resources
CITATIONS
Recommended Reading
-
Atembina L, Boehmer L, Terrell K, et al. Multidisciplinary provider insights to promote adoption of bispecific antibodies to treat cancer in the community. Blood. 2021;138(Supplement 1):4033. doi:10.1182/blood-2021-153794.
-
Carlisle JW, O'Reilly K, Ji XA, et al. Real-world implementation of tarlatamab-dlle therapy for patients with extensive-stage small cell lung cancer and other high-grade neuroendocrine neoplasms. JCO Oncol Pract. Published online July 8, 2026. doi:10.1200/OP-26-00074.
-
Cheema PK, Perdrizet KA, Sangha RS, et al. Early experience with tarlatamab (T-cell engagers) for extensive-stage small cell lung cancer (ES-SCLC) in Canada: lessons learned and implementation strategies. Curr Oncol. 2026;33(2):84. Published January 31, 2026. doi:10.3390/curroncol33020084.
-
Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143(16):1565-1575. doi:10.1182/blood.2023022432.
-
Garfall AL, Banerjee R, Frenzel L, et al. A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Front Oncol. 2025;15:1630146. Published July 30, 2025. doi:10.3389/fonc.2025.1630146.
-
Gonugunta AS, Haider A, Mohlere V, Aljurf M, Hashmi S, Abid MB. Bispecific antibodies in hematologic malignancies in the outpatient and community settings. Adv Hematol. 2026;2026:4529571. Published May 7, 2026. doi:10.1155/ah/4529571.
-
Lee DW, Santomasso BD, Meyer FL, et al. ASTCT consensus grading for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758.
-
Lund T, Khandanpour C, Anguille S, et al. European expert panel consensus on outpatient administration of teclistamab and talquetamab in patients with multiple myeloma: feasibility, key considerations, and future directions. Eur J Haematol. 2025;115(4):358-366. doi:10.1111/ejh.14444.
-
Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol. Published online September 11, 2024. doi:10.6004/jadpro.2024.15.8.15.
-
Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2):e001511. doi:10.1136/jitc-2020-001511.
-
Oranges K, Duffy KA, McDonough S, et al. Real-world pediatric blinatumomab administration: access to outpatient care delivery and impact of a hospital-dispensed model. Pediatr Blood Cancer. 2026;73(7):e70314. doi:10.1002/1545-5017.70314.
-
Pelland AA, Dumas M, Lemieux-Blanchard É, et al. Perspectives on outpatient delivery of bispecific T-cell engager therapies for multiple myeloma. Curr Oncol. 2025;32(4):238. Published April 18, 2025. doi:10.3390/curroncol32040238.
-
Puttkammer JR, Barreto JN, Jensen CJ, et al. Outpatient management of bispecific related toxicities: an observational study of safety outcomes and resource utilization. JCO Oncol Pract. 2026;22(1):83-90. doi:10.1200/OP-24-00930.
-
Rahbari KJ, Mijares RDT, Kennedy K, et al. Outpatient administration of bispecific antibody therapy for hematologic malignancies: a practical guide. JCO Oncol Pract. Published online December 4, 2025. doi:10.1200/OP-25-00652.
-
Resnick Y, Boland P, Winters JP. Implementation of a model program at an independent community oncology practice for the outpatient administration of B-cell maturation antigen-directed bispecific antibody step-up doses. JCO Oncol Pract. Published online April 23, 2026. doi:10.1200/OP-25-00585.
-
Scott SA, Roberts DL, Gupta VA, et al. Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting oral abstract. Clin Lymphoma Myeloma Leuk. 2025;25(9):656-660. doi:10.1016/j.clml.2025.04.002.
-
Song Y, Zhou X, Wang L. Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care. Front Oncol. 2026;16:1859755. Published June 9, 2026. doi:10.3389/fonc.2026.1859755.
WITH GRATITUDE
Acknowledgements
Our heartfelt gratitude to all who contributed key insights to the development of these resources, including:
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Tara Graff, DO, MS
Stephen Clark, PharmD, BCOP
Stephanie Waddoups, RN, BSN
Sam Abdelghany, PharmD, MHA, BCOP
Nick Bouchard, PharmD
Maddie Koppin, PharmD
Melinda Rhoades, PharmD, BCOP
Mike Seppelfrick, PharmD
Man-Yee Merl, PharmD, BCOP
Nicholas Bitz, PharmD, MBA, MSPGx
Kristin Kingma, DNP, RN, AGCNS-BC, OCN
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, FHOPA
Kevin Krueger, PharmD, MBA
Joyce Wong, MD
Denise Lougee, MSPAS, RPA-C
Eden Biltibo, MD, MSCI
Emilie Aschenbrenner, PharmD, BCOP
Jane Osterson, RN
Justin Konkol, PharmD, BCPS
Corey Jordan, PharmD
C. Brooke Adams, PharmD, BCOP
Bradley Yelvington, PharmD, BCOP
Bob Phelan, RPh
Allison Mendoza, PharmD
Ready to Bring BTCE Best Practices to Your Team?
Join NCODA’s community of 16,000+ oncology professionals for full access to the Immunotherapy Hub and our entire clinical resource library.